Piracetam: what does this study show?
Single-blind comparison of piracetam, oxiracetam and placebo in older adults. Dose, sample size and duration are not reported in the abstract.
The authors reported improvements in clinical and neurophysiological measures, with larger effects for oxiracetam than piracetam.
The sparse abstract supplies no effect sizes or usable regimen. Single blinding and a disease population limit conclusions about healthy-person cognitive enhancement.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
The sparse abstract supplies no effect sizes or usable regimen. Single blinding and a disease population limit conclusions about healthy-person cognitive enhancement.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.